Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
暂无分享,去创建一个
H. Pass | D. Chia | L. Goodglick | M. Thornquist | M. Tsao | J. Melamed | L. Chiriboga | J. Donington | Geoffrey Liu | G. Goodman | M. Carbone | C. Goparaju | M. de Perrot | M. Huflejt | M. Harbut | S. Levin
[1] K. Nackaerts,et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] In Gyu Kim,et al. Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. , 2011, International journal of oncology.
[3] K. Hess,et al. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment , 2011, Molecular Cancer.
[4] Wun-Jae Kim,et al. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling , 2011, Clinical Cancer Research.
[5] A. Fiorelli,et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. , 2011, Interactive cardiovascular and thoracic surgery.
[6] F. Han,et al. Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. , 2011, Neoplasma.
[7] T. Nakano,et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. , 2011, Respiratory medicine.
[8] Wun-Jae Kim,et al. Imaging , Diagnosis , Prognosis EFEMP 1 as a Novel DNA Methylation Marker for Prostate Cancer : Array-Based DNA Methylation and Expression Profiling , 2011 .
[9] L. Su,et al. Fibulin‐3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity , 2010, The Journal of pathology.
[10] F. Segade. Molecular evolution of the fibulins: implications on the functionality of the elastic fibulins. , 2010, Gene.
[11] L. Marmorstein,et al. Focus on molecules: fibulin-3 (EFEMP1). , 2010, Experimental eye research.
[12] I. Shih,et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions , 2010, Journal of Cellular and Molecular Medicine.
[13] M. Kanda,et al. Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1, EFEMP1, a Novel Tumor-Suppressor Gene Detected in Hepatocellular Carcinoma Using Double Combination Array Analysis , 2010, Annals of Surgical Oncology.
[14] Bin Hu,et al. Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion , 2009, Molecular Cancer Research.
[15] H. Pass,et al. Current status of screening for malignant pleural mesothelioma. , 2009, Seminars in thoracic and cardiovascular surgery.
[16] N. Paul,et al. Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] Susanne Seitz,et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker , 2009, International journal of cancer.
[18] J. J. Moore,et al. Differential expression of fibulin family proteins in the para-cervical weak zone and other areas of human fetal membranes. , 2009, Placenta.
[19] Helmut Blum,et al. EFEMP1 Expression Promotes In vivo Tumor Growth in Human Pancreatic Adenocarcinoma , 2009, Molecular Cancer Research.
[20] Jian Yu,et al. Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation , 2007, Clinical Cancer Research.
[21] R. Timpl,et al. A Comparative Analysis of the Fibulin Protein Family , 2007, Journal of Biological Chemistry.
[22] S. Bhattacharya,et al. Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction. , 2006, Investigative ophthalmology & visual science.
[23] W. Schiemann,et al. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. , 2006, Cancer research.
[24] D. V. Vander Jagt,et al. Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression. , 2005, Investigative ophthalmology & visual science.
[25] Zhandong Liu,et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. , 2005, The New England journal of medicine.
[26] Sorin Draghici,et al. Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.
[27] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] G. Omenn,et al. The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts. , 1997, American journal of industrial medicine.
[29] M. Mattei,et al. Human fibulin-1D: molecular cloning, expression and similarity with S1-5 protein, a new member of the fibulin gene family. , 1997, Matrix biology : journal of the International Society for Matrix Biology.
[30] T. Sasaki,et al. Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. , 1996, European journal of biochemistry.
[31] V. Rusch,et al. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. , 1996, Lung cancer.
[32] M. Zweig,et al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.
[33] I. Selikoff,et al. Use of death certificates in epidemiological studies, including occupational hazards: variations in discordance of different asbestos-associated diseases on best evidence ascertainment. , 1992, American journal of industrial medicine.
[34] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[35] C. Metz. Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.